Skip to main content
. 2018 Jun 12;4:JGO.18.00018. doi: 10.1200/JGO.18.00018

Fig 3.

Fig 3

Comparison of the median progression-free survival (PFS) between patients with colorectal cancer and type II diabetes mellitus treated with metformin (group A, green line) and those treated with other antidiabetic medications (group B, blue line). In group A, the median PFS was 47 months (95% CI, 15 to 79 months), and in group B, the median PFS was 21 months (95% CI, 13 to 29 months; P = .016). The 5-year PFS rate for group A was 48% and 30% for group B.